Abstracts Presented at the 34th Annual International Prostate Cancer Update Conference

Twenty-three abstracts were accepted into the program at the 34th Annual International Prostate Cancer Update and were presented at the end of relevant sessions as video abstracts. All submitted video presentations are shown below; for a PDF copy of the abstract book please click here.

Presented with support from:

Abstract winners from the 34th Annual International Prostate Cancer Update Conference

First Place
Scoping Review of RCTs on Exercise, Nutrition, and Psychologic Support for Prostate Cancer
Second Place
Impact Of a Rash Management Guide On Incidence And Severity Of Rash With Apalutamide: Experience from The Apa-RP Study In High-Risk Localized Prostate Cancer
Third Place
Prostatype® Test, Uses the Expression Profiles of Three Embryonic Cancer Stem Cell Genes, PSA, T-Stage and Biopsy Gleason Score

Abstracts from 34th Annual International Prostate Cancer Update

Real-World Clinical Outcomes by Risk Classification in Medicare Patients with Localized Prostate Cancer Treated with Radical Prostatectomy
The Forsvall Double Needle – A Future Needle Design Aiming to Improve Tissue Collection in Prostate Biopsy
Testosterone Nadir and Clinical Outcomes In Patients Treated With Triptorelin Pamoate: A Retrospective Pooled Analysis Of Three Phase III Studies
Performance Of FDA-Approved PSMA-Targeted Radiopharmaceuticals for The Detection Of Recurrent Prostate Cancer: A Systematic Literature Review
Physical Isolation of Tumor Associated ctDNA Fragments for Novel Prostate Cancer Liquid Biopsy
MYB Exhibits Racially Disparate Expression and Clinicopathologic Association In Prostate Cancer: Significance As A Predictor Of Biochemical Recurrence
Treatment Of Metastatic Castrate-Resistant Prostate Cancer Patient with Two Cycles Of 67Cu SAR-bisPSMA (8 GBq) Leads To Undetectable PSA Level: A Case Report
Evaluating the mtDNA Copy Number in Prostate Cancer Samples
Effect Of Rapid Ultra-Low Prostate-Specific Antigen Decline (UL PSA) In TITAN Patients (pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) who Received Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT)
The Effect of Prior Docetaxel (DOC) Treatment On Efficacy And Safety Of Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) In Patients (pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) From TITAN
Niraparib (NIRA) With Abiraterone Acetate Plus Prednisone (AAP) As First-Line (1L) Therapy In Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair (HRR) Gene Alterations: Three-Year Update And Final Analysis (FA) Of MAGNITUDE
Presence Of Somatic/Germline Homologous Recombination Repair (HRR) Mutations And Outcomes In Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (Pts) Receiving First-Line (1L) Treatment Stratified By BRCA Status
Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (PSMAfore)
Initial Experience with Low Field MR-guided Prostate Cryoablation: Treatment Planning and Clinical Workflow
Accurate Prostate Biopsies Using Low-Field Portable Interventional MRI In an Ambulatory Surgical Center
Efficacy and Safety of Darolutamide in Combination with Androgen-Deprivation Therapy And Docetaxel in Black Patients From the Randomized ARASENS Trial
Survival Outcomes in Veterans with Non-metastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis by Race and Ethnicity
Efficacy and Safety of Darolutamide in Combination with Androgen-Deprivation Therapy and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS Study
Association Of Prostate-Specific Antigen (PSA) Response and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Results From The Phase 3 ARASENS Trial